Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women

被引:43
|
作者
Min, SS
Corbett, AH
Rezk, N
Cu-Uvin, S
Fiscus, SA
Petch, L
Cohen, MS
Kashuba, ADM
机构
[1] Univ N Carolina, Sch Pharm, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA
[4] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[5] Brown Univ, Sch Med, Providence, RI 02912 USA
关键词
female genital tract; pharmacokinetic; antiretroviral concentration; HIV-1; protease inhibitor; nonnucleoside reverse transcriptase inhibitor;
D O I
10.1097/00126334-200412150-00008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The pharmacokinetics of antiretrovirals (ARVs) in the female genital tract (FGT) are likely to influence vertical and sexual transmission of HIV, the development of viral resistance, and post-exposure prophylaxis regimens. This study is the first to compare ARV concentrations in direct aspirates of cervicovaginal fluid (CVF) and blood plasma (BP). This unique method provides direct assessment of concentrations without the confounding of cervicovaginal lavage dilution. Of 8 ARVs, CVF concentrations ranged from <10% to >100% of BP concentrations. These large differences in CVF penetration suggest that further research into ARV pharmacokinetics and drug efficacy in the FGT is necessary.
引用
收藏
页码:1577 / 1580
页数:4
相关论文
共 50 条
  • [31] Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase
    Grob, PM
    Cao, YZ
    Munchmore, E
    Ho, DD
    Norris, S
    Pav, JW
    Shih, CK
    Adams, J
    NATURE MEDICINE, 1997, 3 (06) : 665 - 670
  • [32] Efavirenz is a potent nonnucleoside reverse transcriptase inhibitor of HIV type 1 replication in microglia in vitro
    Albright, AV
    Erickson-Viitanen, S
    O'Connor, M
    Frank, I
    Rayner, MM
    González-Scarano, F
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (15) : 1527 - 1537
  • [33] HBY 097 - a second-generation nonnucleoside inhibitor of the HIV-1 reverse transcriptase
    Kleim, JP
    TRENDS IN DRUG RESEARCH II, 1998, 29 : 117 - 119
  • [34] Comparison of protease inhibitor [PI] and non-nucleoside reverse transcriptase inhibitor [NNRTI] concentrations [CONC] in the male [M] and female [F] genital tract [GT].
    Kashuba, ADM
    Min, SS
    Corbett, AH
    Rezk, N
    Cohen, MS
    JOURNAL OF INVESTIGATIVE MEDICINE, 2003, 51 : S382 - S382
  • [37] Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity
    Lake, Jordan E.
    McComsey, Grace A.
    Hulgan, Todd
    Wanke, Christine A.
    Mangili, Alexandra
    Walmsley, Sharon L.
    Currier, Judith S.
    OPEN FORUM INFECTIOUS DISEASES, 2015, 2 (02):
  • [38] Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors
    Galli, M
    Ridolfo, AL
    Adorni, F
    Gervasoni, C
    Ravasio, L
    Corsico, L
    Gianelli, E
    Piazza, M
    Vaccarezza, M
    Monforte, AD
    Moroni, M
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 29 (01) : 21 - 31
  • [39] Boosted Protease Inhibitor-Based or Nonnucleoside Reverse Transcriptase-Based HAART: Is There a Best Choice for Antiretroviral-Naive HIV-1 Infected Patients?
    Cuzin, Lise
    Allavena, Clotilde
    Morlat, Philippe
    Dellamonica, Pierre
    AIDS REVIEWS, 2008, 10 (04) : 205 - 211
  • [40] Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA
    Raffi, F
    Bonnet, B
    Ferré, V
    Esnault, JL
    Perré, P
    Reliquet, V
    Leautez, S
    Bouillant, C
    Vergnoux, O
    Weinbreck, P
    CLINICAL INFECTIOUS DISEASES, 2000, 31 (05) : 1274 - 1278